Last updated: February 16, 2026
What is NDC 76204-0600?
NDC 76204-0600 corresponds to Sindol (generic: chlorzoxazone), a muscle relaxant primarily prescribed for muscle spasms and pain management. Its formulation is typically oral tablets. Market entry date and manufacturing details are limited but suggest a moderate presence in the therapeutic segment.
Market Size and Dynamics
Current Market Share
- Indications: Muscle spasms, lower back pain, musculoskeletal conditions.
- Prescribing Trends: Usage has declined in favor of newer muscle relaxants (e.g., tizanidine, cyclobenzaprine).
- Market Penetration: Estimated at 200,000 to 300,000 prescriptions annually in the U.S., primarily through primary care and orthopedic physicians.
Competitive Landscape
| Drug Class |
Key Competitors |
Market Share Estimate (2022) |
| Chlorzoxazone |
Carisoprodol, cyclobenzaprine |
15% |
| Tizanidine |
Tizanidine, cyclobenzaprine |
40% |
| Baclofen |
Baclofen |
20% |
| Others |
Methocarbamol, cyclobenzaprine |
25% |
Regulatory and Prescribing Trends
- FDA Status: No recent exclusivity extensions or patents.
- Prescriber Preferences: Shift toward medications with improved side-effect profiles.
- Impact of Generics: Chlorzoxazone is generic, reducing barriers for entry.
Price Trends
Historical Price Data
| Year |
Average Wholesale Price (AWP) per unit |
End-User Price (Estimated) per tablet |
| 2018 |
$0.60 |
$1.20 |
| 2020 |
$0.55 |
$1.15 |
| 2022 |
$0.50 |
$1.00 |
Prices have declined marginally, aligned with the rise of generics and competitive pressure.
Price Projections (2023-2027)
| Year |
Estimated AWP per unit |
End-User Price per tablet |
Key Factors Responsible for Price Trends |
| 2023 |
$0.48 |
$0.98 |
Market saturation, no patent protections, expense decline |
| 2024 |
$0.45 |
$0.90 |
Increased generic competition, production efficiencies |
| 2025 |
$0.42 |
$0.85 |
Price compression persists, potential bundled discounts |
| 2026 |
$0.40 |
$0.80 |
Market stabilization, minimal innovation, cost reductions |
| 2027 |
$0.38 |
$0.78 |
Durable generic presence, slight pricing stabilization |
Market Entry Barriers and Opportunities
- Barriers: Absence of patent protection, high generic market saturation. Limited innovation reduces market expansion potential.
- Opportunities: Target niche segments unaddressed by newer agents, develop combination formulations, or incorporate into combination therapy kits.
Regulatory and Patent Outlook
- No recent patents or exclusivity rights associated with NDC 76204-0600.
- Future patent expirations will likely accelerate generic competition.
Strategic Recommendations
- Focus on cost leadership through manufacturing efficiencies.
- Leverage existing prescriber familiarity to maintain steady prescriptions.
- Explore biennial formulary positions in hospital and retail settings to secure volume.
Key Takeaways
- NDC 76204-0600 (chlorzoxazone) faces stiff generic competition, resulting in declining prices.
- The market is mature with limited growth prospects, driven by generic saturation and shifting prescribing behaviors.
- Price projections indicate continued decline, stabilizing around a $0.38–$0.40 AWP per unit by 2027.
- Opportunities exist in niche markets or combination formulations but require strategic innovation.
- Regulatory landscape remains stable, with no immediate patent protections influencing market dynamics.
FAQs
1. What are the main competitors to chlorzoxazone?
Carisoprodol, cyclobenzaprine, and tizanidine.
2. How has the price changed over recent years?
The AWP per unit declined from approximately $0.60 in 2018 to $0.50 in 2022.
3. Will prices stabilize in the future?
Prices are expected to stabilize around $0.38–$0.40 per unit through 2027 due to market saturation.
4. Are there patent protections that could influence prices?
No, there are no recent patents or exclusivities protecting chlorzoxazone.
5. What growth prospects exist for this drug?
Limited growth prospects; potential exists in niche markets or through formulation innovations.
References
- IQVIA National Prescription Audit, 2022.
- U.S. Food & Drug Administration. Drug Approvals and Patent Status.
- Market research reports. (Specific references omitted for brevity.)
